Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?

Frisullo G Calabrese M Tortorella C Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study. Mult Scler [Epub ahead of print 10 February 2014. DOI: 10.1177/1352458514521311].

Rotondi M Stufano F Lagonigro MS Interferon-β but not glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. J Neuroimmunol 2011; 234: 161-164.

Rotondi M Chiovato L Romagnani S Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007; 28: 492-520.

Mikol DD Barkhof F Chang P Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-914.

Caraccio N Dardano A Manfredonia F Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: Predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005; 90: 4133-4137.